SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001867096-23-000047
Filing Date
2023-03-29
Accepted
2023-03-29 16:23:08
Documents
2
Period of Report
2023-03-27

Document Format Files

Seq Description Document Type Size
1 FORM 3 wf-form3_168012137493549.html 3  
1 FORM 3 wf-form3_168012137493549.xml 3 1734
2 EX 24 POA RICKI FAIRLEY ex-24.htm EX-24 3011
  Complete submission text file 0001867096-23-000047.txt   6149
Mailing Address 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601
Business Address 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601 844-445-5704
Xeris Biopharma Holdings, Inc. (Issuer) CIK: 0001867096 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address XERIS BIOPHARMA HOLDINGS, INC. 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601
Business Address
Fairley Ricki Louise (Reporting) CIK: 0001971350 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40880 | Film No.: 23775537